- Global Pharma News & Resources

Gurnet Point Capital Appoints Stacey Seltzer as Partner

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gurnet Point Capital ("Gurnet Point”), a private investment firm focused on the healthcare sector that is part of the B-FLEXION group of investment partnerships and direct holdings, today announced the appointment of Stacey Seltzer as a new Partner to further strengthen the firm’s management team.

An experienced life sciences investor, Ms. Seltzer most recently served as Partner at Aisling Capital, where she led or co-led more than 15 transactions with growth-stage life science companies. Earlier, she was at Schering-Plough, a pharmaceuticals company, where she held roles in business development, marketing and sales. Ms. Seltzer holds an MBA from The Wharton School and a Master’s and Bachelor’s in Molecular Biophysics and Biochemistry from Yale. At Gurnet Point, she will source deals and lead transactions across the therapeutics space.

“I am thrilled to join Gurnet Point’s talented team, which combines a deep understanding of cutting-edge scientific advancements with the operational expertise needed to scale companies,” said Ms. Seltzer. “I share Gurnet Point’s commitment to bringing transformative treatments to patients and am looking forward to working closely with the team to identify opportunities for new partnerships with promising therapeutics companies.”

“At Gurnet Point, we are driven by our mission of delivering positive health outcomes for patients and the broader community through our partnerships with innovative life sciences and biotechnology companies,” said Travis Wilson, a Partner of the firm since its inception. “We are delighted that Stacey is joining our team, and I look forward to partnering with her and Ron to build upon our successes and strengthen our position as a leading healthcare investor.”

“This is an exciting time for Gurnet Point and I’m confident that our firm will continue to drive lasting value across our life sciences portfolio,” said Ron Cami, Partner of GPC, and a member of the Board of B-Flexion, the firm’s principal investor and owner. “I look forward to working with Travis, Stacey and the rest of Gurnet Point’s team to execute on our strategy and seek out new opportunities to bring our resources and expertise to companies on the forefront of the healthcare industry.”

About Gurnet Point Capital

Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives work closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.


Blair Hennessy, H/Advisors Abernathy / 212-371-5999

Editor Details

  • Company:
    • Businesswire
Last Updated: 03-Nov-2022